Applications · US
Chai Discovery was valued at $3.8B as of 14 July 2026 (reported). Source: Chai Discovery, $400M Series C led by Index Ventures with Kleiner Perkins, Sequoia and Dimension; existing investors including OpenAI and Thrive Capital participating (company release - it states the round, not a post-money).
Generative models for molecular design - antibodies, proteins and other therapeutics designed from scratch, with Chai-3 the current model; named partners include Eli Lilly, Pfizer and Novartis.
Generative models for molecular design - antibodies, proteins and other therapeutics designed from scratch, with Chai-3 the current model; named partners include Eli Lilly, Pfizer and Novartis. The $400M Series C is company-announced, but the $3.8B post-money (roughly triple the $1.3B December 2025 Series B) appears only in trade coverage, not in the release, so the mark is reported. OpenAI has backed the company since its 2024 seed and joined the Series C.
See something wrong or out of date? Suggest a correction (GitHub) or email it. Please include a source.
Last updated 14 July 2026. Follow Chai Discovery in any feed reader to hear when its valuation moves.
State of AI World maps every significant AI company, what it is worth and how it is connected. Every number carries a source and an as-of date; see the methodology. Data is free to reuse with credit: open data. · All companies · Daily digest · Corrections and contact